SAB Biotherapeutics SABS Stock
SAB Biotherapeutics Price Chart
SAB Biotherapeutics SABS Financial and Trading Overview
| SAB Biotherapeutics stock price | 4.68 USD |
| Previous Close | 0.88 USD |
| Open | 0.9 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1800 |
| Day's Range | 0.87 - 0.91 USD |
| 52 Week Range | 0.37 - 1.63 USD |
| Volume | 38.82K USD |
| Avg. Volume | 1.36M USD |
| Market Cap | 45.61M USD |
| Beta (5Y Monthly) | 1.41467 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.64 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.2 USD |
SABS Valuation Measures
| Enterprise Value | 36.58M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.0568182 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.5963783 |
| Price/Book (mrq) | 1.8698347 |
| Enterprise Value/Revenue | 2.885 |
| Enterprise Value/EBITDA | -1.397 |
Trading Information
SAB Biotherapeutics Stock Price History
| Beta (5Y Monthly) | 1.41467 |
| 52-Week Change | -21.98% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.63 USD |
| 52 Week Low | 0.37 USD |
| 50-Day Moving Average | 0.83 USD |
| 200-Day Moving Average | 0.78 USD |
SABS Share Statistics
| Avg. Volume (3 month) | 1.36M USD |
| Avg. Daily Volume (10-Days) | 64.46K USD |
| Shares Outstanding | 50.4M |
| Float | 35.81M |
| Short Ratio | 0.76 |
| % Held by Insiders | 29.55% |
| % Held by Institutions | 8.14% |
| Shares Short | 428.07K |
| Short % of Float | 1.20% |
| Short % of Shares Outstanding | 0.85% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -213.53% |
| Operating Margin (ttm) | -233.49% |
| Gross Margin | -118.021% |
| EBITDA Margin | -206.43% |
Management Effectiveness
| Return on Assets (ttm) | -33.60% |
| Return on Equity (ttm) | -82.48% |
Income Statement
| Revenue (ttm) | 12.68M USD |
| Revenue Per Share (ttm) | 0.28 USD |
| Quarterly Revenue Growth (yoy) | -95.099% |
| Gross Profit (ttm) | -12534332 USD |
| EBITDA | -26180640 USD |
| Net Income Avi to Common (ttm) | -27080488 USD |
| Diluted EPS (ttm) | -0.6 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 13.06M USD |
| Total Cash Per Share (mrq) | 0.26 USD |
| Total Debt (mrq) | 5.46M USD |
| Total Debt/Equity (mrq) | 22.38 USD |
| Current Ratio (mrq) | 1.1 |
| Book Value Per Share (mrq) | 0.484 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -15527503 USD |
| Levered Free Cash Flow (ttm) | -6192746 USD |
Profile of SAB Biotherapeutics
| Country | United States |
| State | SD |
| City | Sioux Falls |
| Address | 2100 East 54th Street North |
| ZIP | 57104 |
| Phone | 605 679 6980 |
| Website | https://www.sabbiotherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 56 |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
Q&A For SAB Biotherapeutics Stock
What is a current SABS stock price?
SAB Biotherapeutics SABS stock price today per share is 4.68 USD.
How to purchase SAB Biotherapeutics stock?
You can buy SABS shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for SAB Biotherapeutics?
The stock symbol or ticker of SAB Biotherapeutics is SABS.
Which industry does the SAB Biotherapeutics company belong to?
The SAB Biotherapeutics industry is Biotechnology.
How many shares does SAB Biotherapeutics have in circulation?
The max supply of SAB Biotherapeutics shares is 9.23M.
What is SAB Biotherapeutics Price to Earnings Ratio (PE Ratio)?
SAB Biotherapeutics PE Ratio is now.
What was SAB Biotherapeutics earnings per share over the trailing 12 months (TTM)?
SAB Biotherapeutics EPS is -7.64 USD over the trailing 12 months.
Which sector does the SAB Biotherapeutics company belong to?
The SAB Biotherapeutics sector is Healthcare.
SAB Biotherapeutics SABS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}